Skip to main content
Clinical Trials/JPRN-UMIN000023101
JPRN-UMIN000023101
Completed
未知

[F-18]FDG and [C-11]Acetate PET/CT study for refractory diseases - [C-11]Acetate PET/CT study

Tokyo Medical and Dental University0 sites40 target enrollmentJuly 15, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Tokyo Medical and Dental University
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 15, 2016
End Date
March 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • i. serum glucose level greater than 200mg/dl ii. pregnancy or possible iii. patients can't demonstrate informed consent iv. early gastric cancer in which \[F\-18]FDG PET/CT isn't applicable for covered health insurance

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancer
JPRN-UMIN000053550iigata University Medical and Dental Hospital165
Completed
Not Applicable
Integrated 18F-FDG PET/CT in the staging of patients with suspected primary ovarian cancer.
NL-OMON29961Academisch Ziekenhuis Maastricht20
Active, not recruiting
Phase 1
Study to see if new research scans can show how treatment affects the blood supply to kidney cancersPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-002833-20-GBOxford University Hospitals NHS Trust10
Completed
Not Applicable
11C-MET PET(/CT) vs 18F-FDG PET(/CT) in the follow-up of differentiated thyroid cancer*
NL-OMON32909niversitair Medisch Centrum Groningen40
Not yet recruiting
Not Applicable
Management and prognosis of breast cancer through FDG PET/CTHealth Condition 1: null- Breast Cancer (Retrospective data of Breast Cancer Patients will be collected)
CTRI/2012/09/002966ot applicable Thesis Protocol500